NEW YORK & PETACH TIKVAH, Israel–(Business Wire)–
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult
stem cell technologies and therapeutics today announced that Rami Efrati,
BrainStorm`s CEO, will be presenting at the 9th National Life Science and
Technology Week ILSI-Biomed Conference, Israel 2010. The presentation will be
given on Monday June 14, 2010 during the BioPharma Session being held from 4:30
p.m. to 6:30 p.m. Israel time.
Mr. Efrati`s presentation will discuss the Company`s achievements and milestones
to date as well BrainStorm`s upcoming ALS clinical trials. Mr. Efrati along with
other members of BrainStorm will meet with pharmaceutical and biotech companies
engaged in stem cell technologies that are attending the conference.
For more information about ILSI-Biomed Israel 2010 please visit
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem
cell therapeutic products, derived from autologous (self) bone marrow cells, for
the treatment of neurodegenerative diseases. The patent pending technology is
based on discoveries made by the scientific team led by Professor Eldad Melamed,
former Head of Neurology at Rabin Medical Center, and cell biologist Prof.
Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical
Research Center of Tel-Aviv University. The technology allows for the
differentiation of bone marrow-derived stem cells into functional neurons and
astrocytes, as demonstrated in animal models. The Company holds rights to
develop and commercialize the technology through an exclusive, worldwide
licensing agreement with Ramot at Tel Aviv University Ltd., the technology
transfer company of Tel-Aviv University. The Company’s current focus is on ALS,
although its technology has promise for treating several other diseases
including MS, Huntington’s disease and stroke.
Safe Harbor Statement
Statements in this announcement other than historical data and information
constitute “forward-looking statements” and involve risks and uncertainties that
could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ
materially from those stated or implied by such forward-looking statements. The
potential risks and uncertainties include risks associated with BrainStorm’s
limited operating history, history of losses; minimal working capital,
dependence on its license to Ramot’s technology; ability to adequately protect
the technology; dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors detailed in
BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q
available at http://www.sec.gov. The Company does not undertake any obligation
to update forward-looking statements made by us.
BrainStorm Cell Therapeutics
Rami Efrati, CEO, +972-3-9236384
Copyright Business Wire 2010